scholarly journals Prognostic Role of Circulating Tumor Cells ( CTCS ) in Metastatic Renal Cell Carcinoma: A Large, Multicenter Prospective Trial

2021 ◽  
Author(s):  
Umberto Basso ◽  
Antonella Facchinetti ◽  
Elisabetta Rossi ◽  
Marco Maruzzo ◽  
Vincenza Conteduca ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prospective Trial ◽  
Prognostic Role

Role of circulating tumor cells in patients with metastatic clear-cell renal cell carcinoma

2020 ◽  
Author(s):  
Brusabhanu Nayak ◽  
Sridhar Panaiyadiyan ◽  
Prabhjot Singh ◽  
Subhradip Karmakar ◽  
Seema Kaushal ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Circulating tumor cells status in metastatic renal cell carcinoma (mRCC) after metastasectomy (RESORT trial)

2015 ◽  
Vol 26 ◽  
pp. vi62
Author(s):  
E. Verzoni ◽  
P. Grassi ◽  
V. Cappelleti ◽  
C. Maggi ◽  
R. Montone ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib

2021 ◽  
pp. 030089162110339
Author(s):  
Elena Bolzacchini ◽  
Monica Giordano ◽  
Lorenza Bertù ◽  
Marco Bregni ◽  
Olga Nigro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Multivariate Analysis ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Clinical Data ◽  
Renal Cell ◽  
Prognostic Role ◽  
Lymphocyte Ratio ◽  
Poor Risk

Background: Hemochrome parameters at the diagnosis of metastatic renal cell carcinoma (mRCC) and the development of macrocytosis during sunitinib therapy are considered prognostic. Objective: To evaluate the prognostic role of hematologic parameters and macrocytosis in mRCC treated with sunitinib. Methods: We analyzed clinical data of 100 patients with mRCC treated with sunitinib as first-line therapy in a retrospective multicenter study. We calculated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) at baseline and erythrocyte mean corpuscular volume (MCV) during therapy. We considered the following cutoffs: NLR >3, PLR >150, LMR <3, and MCV >100 fl. Clinical data histology, prior nephrectomy, Fuhrman grading, metastatic sites, Memorial Sloan-Kettering Cancer Center score, and Heng score were collected. Overall survival (OS) and progression-free survival (PFS) were calculated. Univariate and multivariate analysis using Cox regression model with time-dependent (macrocytosis) covariate were applied. Results: At the univariate analysis, low LMR was associated with shorter PFS and OS ( p = 0.02 and p = 0.06, respectively). High PLR was associated with worse PFS ( p = 0.005); median OS was 23 vs 28 months ( p = 0.13). At the multivariate analysis, poor risk (Heng score), low LMR, and high PLR were associated with shorter PFS (hazard ratio 7.1, 1.5, and 2, respectively); poor PS and poor risk (Heng score) were related to worst OS. Macrocytosis was observed in 26 patients and was not prognostic of survival. Conclusions: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.

scholarly journals Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (9) ◽  
pp. 14995-15003 ◽  
Author(s):  
Li Liu ◽  
Ying Xiong ◽  
Wei Xi ◽  
Jiajun Wang ◽  
Yang Qu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Role
Sign in / Sign up

Export Citation Format

Share Document